Cefiderocol + Standard of Care

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gram-negative Bacterial Infections

Conditions

Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI), Hospital Acquired Pneumonia (HAP), Ventilator-acquired Pneumonia, Complicated Urinary Tract Infection (cUTI), Sepsis

Trial Timeline

Aug 21, 2020 → Feb 6, 2023

NCT ID

NCT04335539

About Cefiderocol + Standard of Care

Cefiderocol + Standard of Care is a phase 2 stage product being developed by Shionogi for Gram-negative Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT04335539. Target conditions include Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI).

What happened to similar drugs?

0 of 2 similar drugs in Gram-negative Bacterial Infections were approved

Approved (0) Terminated (1) Active (1)

❌Ceftolozane-Tazobactam + MeropenemMerckPhase 3

🔄tigecyclinePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06086626	Phase 2	Completed	Mar 14, 2024	Mar 31, 2025	Gram-Negative Bacterial Infections
NCT04335539	Phase 2	Completed	Aug 21, 2020	Feb 6, 2023	Gram-negative Bacterial Infections
NCT04215991	Phase 2	Completed	Feb 19, 2020	Sep 17, 2024	Gram-negative Bacterial Infections

Competing Products

14 competing products in Gram-negative Bacterial Infections

See all competitors

Product	Company	Stage	Hype Score
Cefiderocol + Standard of Care	Shionogi	Phase 2	35
Cefiderocol	Shionogi	Pre-clinical	26
Cefiderocol + Standard of Care	Shionogi	Phase 2	35
HRS-8427	Jiangsu Hengrui Medicine	Phase 1	29
Part A: ATM-AVI Single Dose, Cohorts 1-4 + Part B: Multiple-dose ATM-AVI, Cohorts 1-4	AbbVie	Phase 2	42
IMI/REL + Active Control + Oral Switch	Merck	Phase 2/3	38
IMI/REL FDC	Merck	Phase 1	29
Ceftolozane-Tazobactam + Meropenem	Merck	Phase 3	32
Ceftolozane/Tazobactam 1000/500 mg + Ceftolozane/Tazobactam 30/15 mg/kg + Ceftolozane/Tazobactam 20/10 mg/kg + Ceftolozane/Tazobactam 18/9 mg/kg + Ceftolozane/Tazobactam 12/6 mg/kg	Merck	Phase 1	29
nacubactam + meropenem	Roche	Phase 1	29
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3 + Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3	Pfizer	Phase 2	27
ATM-AVI + BAT	Pfizer	Phase 2	42
tigecycline	Pfizer	Phase 3	40
AN3365 + Placebo	Pfizer	Phase 1	29